2026-09-30 8-K filing
8-K: Item 7.01, Item 8.01, Item 9.01 D1 -0.6% · since -1.8%
2026-09-10 Capital Bull
DYN sees unusual call option volume surge 4,325% 20,532 call options bought in a day, far above average, signaling heightened market interest
D1 -4.0% · +5d -2.0%
13 earlier events › 2026-09-08 Product
Novartis DM1 Drug Phase 3 Failure Draws Attention to DYN's Similar Asset Rival del-desiran missed primary endpoint in Phase 3; DYN's z-basivarsen targets same pathway, spotlight on its differentiating data
D1 -16.4% · +5d -11.9%
2026-09-08 Company
DYN to Present One-Year Data from ACHIEVE Trial Company announced upcoming presentation of one-year data for z-basivarsen in DM1, with comparison to matched natural history cohort
D1 -16.4% · +5d -11.9%
2026-08-14 Insider selling
Insider selling $54.0M (1) D1 -1.0% · +5d +1.6%
2026-08-13 Insider selling
Insider selling $11.4M (5) D1 -0.8% · +5d +0.1%
2026-07-30 Earnings
Earnings report D1 +2.5% · +5d +0.6%
2026-07-20 → 07-29 Regulation Bull
Dyne's z-rostudirsen Granted FDA Priority Review; PDUFA Set for Jan 21, 2027 BLA accepted with Priority Review, key regulatory milestone for exon 51 skipping DMD therapy
D1 -1.2% · +5d +9.3%
› 6 waves of this story2026-07-20 BLA accepted with priority review; PDUFA date Jan 21, 20272026-07-20 Accelerated approval based on dystrophin surrogate; potential US launch Q1 20272026-07-22 Offering funds DMD therapy and DM1 program, bolstering pipeline advancement2026-07-22 Upsized to 18.3M shares at $20.50, closing July 23, expanding from prior $300M plan2026-07-28 FDA cleared IND for DYNE-302 in FSHD, marking the third FORCE platform program to enter clinical development2026-07-29 BLA accepted with Priority Review, key regulatory milestone for exon 51 skipping DMD therapy2026-07-29 8-K filing
8-K: Item 2.02, Item 9.01 D1 -3.1% · +5d +4.3%
2026-07-27 Earnings
Earnings report D1 +4.9% · +5d -1.5%
2026-07-22 8-K filing
8-K: Item 1.01, Item 8.01, Item 9.01 D1 -2.6% · +5d +8.1%
2026-07-20 8-K filing
8-K: Item 8.01 D1 -1.2% · +5d +9.3%
2026-07-06 Insider selling Bear
Insider selling $10.9M (1) D1 -1.0% · +5d +3.5%
2026-06-22 8-K filing
8-K: Item 5.02 D1 +5.4% · +5d +1.9%
2026-06-17 8-K filing
8-K: Item 1.01, Item 2.03 D1 +6.3% · +5d +7.3%
by direction · sourced
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
be the first
🙂 Post
Facts and opinions separated · All items sourced · Not investment advice
